L’activité antipaludique de la ferroquine : de la recherche à la clinique by Biot, Christophe et al.
HAL Id: hal-00642112
https://hal.archives-ouvertes.fr/hal-00642112
Submitted on 16 Sep 2019
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d’enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.
Distributed under a Creative Commons Attribution| 4.0 International License
The antimalarial ferroquine: from bench to clinic.
Christophe Biot, F. Nosten, L. Fraisse, D. Ter-Minassian, Jamal Khalife,
Daniel Dive
To cite this version:
Christophe Biot, F. Nosten, L. Fraisse, D. Ter-Minassian, Jamal Khalife, et al.. The antimalarial
ferroquine: from bench to clinic.. Parasite, EDP Sciences, 2011, 18 (3), pp.207-214. ￿10.1051/para-
site/2011183207￿. ￿hal-00642112￿
207Review
Parasite, 2011, 18, 207-214
THE ANTIMALARIAL FERROQUINE: FROM BENCH TO CLINIC
BIOT C.*, NOSTEN F.**, FRAISSE L.***, TER-MINASSIAN D.****, KHALIFE J.***** & DIVE D.*****
Summary:
Ferroquine (FQ, SSR97193) is currently the most advanced organo-
metallic drug candidate and about to complete phase II clinical 
trials as a treatment for uncomplicated malaria. This ferrocene-
containing compound is active against both chloroquine-susceptible 
and chloroquine-resistant Plasmodium falciparum and P. vivax 
strains and/or isolates. This article focuses on the discovery of FQ, 
its antimalarial activity, the hypothesis of its mode of action, the 
current absence of resistance in vitro and recent clinical trials.
KEY WORDS: malaria, bioorganometallics, drug candidate, ferroquine, 
mechanism of action, resistance.
Résumé : L’ACTIVITÉ ANTIPALUDIQUE DE LA FERROQUINE : DE LA RECHERCHE 
À LA CLINIQUE
La ferroquine (FQ, SSR97193) est actuellement le candidat 
médicament organométallique le plus avancé dans son 
développement industriel et, en tant que traitement du paludisme 
non compliqué, il devrait bientôt voir s’achever des études cliniques 
de phase II. Ce composé à base de ferrocène est extrêmement actif 
contre des isolats et/ou des clones de Plasmodium falciparum et de 
P. vivax sensibles ou résistants à la chloroquine. Cet article présente 
la découverte de la FQ, son activité antipaludique, les hypothèses 
liées à son mode d’action, l’absence actuelle de résistance in vitro 
et, enfin, les récents essais cliniques.
MOTS-CLÉS : paludisme, bio-organométallique, candidat médicament, 
ferroquine, mécanisme d’action, résistance.
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THE MALARIA PROBLEM
With approximately 243 million cases and more than 800,000 deaths reported in 2009, malaria remains the most important human 
parasitic disease. Among the five Plasmodium species 
able to infect human, P. falciparum is responsible for 
most cases of severe disease and death, mainly in 
African children below the age of five. The morbi-
dity caused by P. vivax in tropical countries outside 
of Africa has long been underestimated (Anstey et 
al., 2009, Baird, 2009). Malaria is a factor of poverty 
in endemic countries (Stratton et al., 2008). In the 
absence of an effective vaccine and reliable approa-
ches for vector control, chemotherapy remains the 
corner stone of malaria control. Quinine has been 
the first widely used antimalarial drug. Synthetic deri-
vatives of quinine were the 8-aminoquinoline prima-
quine and the 4-aminoquinoline chloroquine (CQ). 
When resistance to CQ emerged in the late 1950s, the 
strategy was to modify the chemical structure of the 
existing compounds. The synthesis of CQ-like drugs 
led to the discovery of amodiaquine (AQ) and later 
mefloquine (MQ), halofantrine in the United States and 
lumefantrine in China (Baird, 2005). But the pace of 
new drug development has been slow and no new 
antimalarial drugs have been introduced into clinical 
practice since artemether-lumefantrine registered in 
1998 (Olliaro & Wells, 2009). For all new antimala-
rial drugs introduced the risk of resistance can be 
reduced by combination therapy (White, 1999; Nosten 
& White, 2007). In 2006, the WHO guidelines recom-
mended new treatments combining two drugs with 
different mechanisms of action. Treatments containing 
an artemisinin derivative (artemisinin-combination 
therapies, ACTs) are now standard treatment for fal-
ciparum malaria. However, a decline of susceptibility 
to artesunate has been recently reported in the Thai- 
Cambodian border region (Dondorp et al., 2010). So 
the search for new molecules with antimalarial activity 
is more important than ever.
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Many strategies can be used for the search of affor-
dable and efficient antimalarial drugs. These strategies 
include ethnopharmacology (i.e. bio-evaluation of the 
efficiency of traditional medicines), medicinal che-
mistry, combinatorial chemistry and chemical libraries 
screening by high throughput screening, and drug 
design. These strategies have led to the discovery of 
potential antimalarials such as the synthetic endope-
roxides and others (Dhanawat et al., 2009). But the 
clinical development of new compounds is often 
been stopped for various reasons: toxicity, chemistry, 
pharmacology, or economics, and less than one in 
ten promising molecules that have entered the pipe-
line reaches the stage of clinical studies. In the mid-
90s, we extended the strategy developed by Gérard 
Jaouen (Vessieres et al., 1988) in anticancer therapy 
to antimalarial therapy (see Chavain & Biot, 2010 for 
review). The main antimalarials in current use (CQ, 
quinine, mefloquine, artemisinin, atovaquone) were 
modified by introduction of a ferrocenyl moiety in 
their chemical structure. More than 150 ferrocenic 
analogues have been synthesized, by us and others 
(Biot & Dive, 2010). The ferrocenic analogues were 
systematically tested against in vitro cultures of P. falci-
parum with CQ-susceptible and CQ-resistant strains. 
Ferroquine (FQ, SSR97193) was rapidly identified as a 
lead compound to meet candidate nomination require-
ments (Biot et al., 1997). The clinical phase IIb study 
(efficacy/safety in adults, adolescents and children) 
began in 2009 in Africa.
This mini-review will focus on the discovery of FQ, 
its antimalarial activity, the hypothesis of its modes 
of action and recent clinical trials.
THE ORGANOMETALLIC ANTIMALARIAL 
COMPOUND SET
Since 1993, we and others have systematically prepared organometallic versions of the anti-malarials in current use such as CQ, primaquine, 
mepacrine, mefloquine, quinine, artemisinin, and 
atovaquone (see Dive & Biot, 2008 for review). New 
sandwiches and half-sandwiches metal complexes 
(Dunitz et al., 1956) have been synthesized and cha-
racterized. In vitro tests of their antimalarial activity 
were performed. Other organometallic compounds 
with a priori unknown antimalarial activity were still 
screened. A collection of almost 150 compounds 
was made available. Among the organometallic-
drug hybrids, the most interesting compounds were 
the ferrocene-drug hybrids and among those the 
ferrocene-chloroquine hybrids were the most promis-
sing (Fig. 1).
Note here that the ferrocene-artemisitene hybrids 
showed also interesting properties with activities 
equal to artemisinin (Delhaes et al., 2000, Dive & Biot, 
2008). In the ferrocene-CQ hybrids series, we have 
shown that the ferrocene moiety has to be covalently 
flanked by a 4-aminoquinoline and an alkylamine 
(Biot et al., 2006). Ferroquine (FQ, SSR97193) was 
the first compound synthesized by us (Biot et al., 
1997). Later, a second generation of analogues of 
FQ was designed and investigated. For example, we 
synthesized dual molecules including a FQ analogue 
conjugated with a glutathione reductase inhibitor 
or a glutathione depletory (Chavain et al., 2009) 
Nevertheless, this strategy failed to identify a “new” 
lead for a further development. More interestingly, 
amino-alcohols based on the FQ structure are active 
against CQ-susceptible (CQS) and CQ-resistant (CQR) 
clones of P. falciparum. In addition, in this second 
generation of analogues the ferrocenic amino-alcohols 
exert antiviral effects with some selectivity toward 
SARS-CoV infection (Biot et al., 2006b).
ANTIMALARIAL ACTIVITY OF FERROQUINE
ANTIMALARIAL ACTIVITY ON LABORATORY CLONES
FQ antimalarial activity was compared to that of CQ with standard in vitro parasite growth inhibition method, based on tritiated hypoxan-
thin incorporation in erythrocytes infected with P. 
falciparum, incubated 48 hours (Desjardins et al., 
1978). Preliminary studies have shown that FQ was 
equally active as a base, ditartrate or dichlorhydrate 
salts (unpublished results).
Tests results available from 11 studies performed in 
different laboratories and using 19 CQS and CQR P. 
falciparum laboratory adapted clones are represented 
in Fig. 2. The results show that the response to CQ 
can be easily dissociated between susceptible and 
resistant clones, which are spread respectively on 
either sides of the 100 nM IC50 for CQ. However, 
FQ is equally active on both types of clone and is at 
least equally active and often more active than CQ 
on CQS parasites. No resistance to FQ occurred in 
CQR clones and no correlation was found between 
susceptibility to FQ and polymorphism in transport 
proteins implicated in quinoline resistance (Henry et 
al., 2008).
IN VIVO ANTIMALARIAL ACTIVITY IN RODENT MODELS
Antimalarial activity of FQ was tested on various 
rodent malaria strains (P. berghei, P. yoelii, P. vinckei) 
by the standard four day test of Peters (1987) adapted 
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to determine the curative dose. On P. berghei N and P. 
yoelii NS strains, FQ and CQ had a close EC50 (treat-
ment with a decrease in parasitaemia of 50 % at the 
end of assay) and the simple four days test could not 
lead to conclude to a better efficacy of FQ versus CQ. 
But the curative tests are more significant and showed 
that P. berghei and P. vinckei infections were cured in 
presence of 8.3 mg/kg/d of FQ for four days when 
with CQ 30 to 55 mg/kg/d were necessary to cure 
CQS strains and the drug was unable to cure resistant 
strains, even at a toxic dose (Biot et al., 1997, Delhaes 
et al., 2001, Dive & Biot, 2008, Biot & Dive, 2010). 
Moreover, it has been shown that FQ was active not 
only by subcutaneous administration, but also by oral 
route, which was an interesting indication concerning 
the bioavailability of the drug by digestive tract. This 
was further confirmed by additional pharmacokinetic 
studies (Biot & Dive, 2010). 
 
Fig 1. – Scheme of different strategies adopted in synthesis of ferrocene-CQ hybrids.
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As FQ is a racemic compound. The two stereoisomers 
were synthetized and showed an antimalarial activity 
similar to that of the parent compound in vitro (Del-
haes et al., 2002).
METABOLIZATION AND ACTIVITY OF METABOLITES
It was first postulated that the metabolism of FQ 
may share a common pathway with that of CQ and 
potential metabolites (N-monodemethyl-FQ and N-
didemethyl-FQ) were synthesized and tested (Biot et 
al., 1999). The metabolism of FQ was then studied in 
details in vitro and enabled to determine its degra-
dation pathway (Daher et al., 2006a). In vitro FQ is 
mainly metabolized to a major N-monodemethylated 
metabolite, SSR97213 (EVT0233) and to a further 
potential metabolite that is an N-didemethylated com-
pound. Antimalarial activity of N-monodemethyl-FQ 
was found to be comparable to that of parent com-
pounds on two CQS clones and remained much more 
active than CQ on two CQR clones. On the another 
hand, N-didemethyl-FQ had a decreased activity on 
CQR clones, mainly if IC90 of compounds is taken into 
account (Daher et al., 2006a). 
EFFICACY ON CLINICAL ISOLATES
Compounds were evaluated with standard in vitro 
parasite growth inhibition methods, in erythrocytes 
infected with P. falciparum, incubated at least 24 
hours with the drugs. The antimalarial activity of FQ 
(SSR97193) on blood clinical isolates (CQS, CQR, and 
multi-drug resistant isolates) infected by P. falciparum 
was assessed in seven different studies of African 
patients (Senegal, Gabon) (Pradines et al., 2001 & 
2002; Atteke et al., 2003; Kreidenweiss et al., 2006), 
or southeast Asian patients (Chim et al., 2004; Barends 
et al., 2007) in comparison with existing antimalarial 
drugs. Data on FQ, CQ, and artesunate are reported 
in Table I.
Taking all these studies together, FQ was evaluated on 
534 clinical isolates, 220 from Southeast Asia and 314 
from Africa. In all these studies, FQ, like artesunate, 
displayed a very potent antimalarial activity against P. 
falciparum (range IC50 below 30 nM [13 ng/mL] for FQ 
and below 4 nM [1.5 ng/mL] for artesunate) with equal 
efficacy upon CQS and CQR clinical isolates (resistant 
isolates, with IC50 over 100 nM, represented from 32 % 
to 100 % of samples). 
In addition, in the study from Thailand the main FQ in 
vivo metabolite (SSR97213) was investigated (Barends 
et al., 2007). SSR97213 was shown to be highly potent 
against P. falciparum (N = 64, IC50 = 37 nM with 95 % 
confidence intervals [CIs] = 34.3 to 39.9 nM, or IC50 = 
16.0 ng/mL with 95 % CIs = 14.9 to 17.3 ng/mL) on 
all the clinical isolates. To investigate whether P. vivax 
was sensitive to FQ a study was conducted in north-
western Thailand on 63 isolates collected from October 
2006 to April 2009 to examine the effects of FQ and its 
demethylated metabolite (SSR97213) on the ring stage 
and the schizont maturation by microscopy. All sam-
ples were collected from patients with acute P. vivax 
who had mono-species parasitaemia of > 100/500 
white blood cells. FQ was found to have a potent ex 
Fig 2. – Susceptibility of 19 laboratory 
P. falciparum clones to CQ and FQ 
compiled from 11 different published 
studies.
IC50 for CQ for each clone tested (l). 
+ IC50 for FQ for each clone tested 
(+). The doted line indicate the thres-
hold of resistance to CQ (Le Bras & 
Ringwald, 1990).
References associated to each clone 
tested: 3D7 (1, 6, 8, 9, 10); HB3 (1, 7, 
9, 10); D10 (2, 3, 4, 5); W2 (1, 6, 8, 
9, 10); K1 (2, 3, 4, 5); FCR3 (1, 6, 11); 
Dd2 (7, 10, 11); D6, 106/1, IMT8425, 
IMT10336, FCM39, IMT Bres, IMT 
K14, IMT K2, IMT K4, IMT L1, IMT 
Vol, Bre1 (1).
References: 1: Henry et al., 2008; 2: 
Beagley et al., 2002; 3: Beagley et al., 
2003, 4: Blackie et al., 2007; 5: Blackie 
& Chibale 2008; 6 Biot et al., 2006b; 7: 
Biot et al., 1999; 8: Biot et al., 2006a; 
9: Daher et al., 2006a; 10: Daher et al., 
2006b; 11: Delhaes et al., 2001.
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vivo effect on P. vivax schizont maturation (median 
IC50 = 15 nM; 75 % CIs = 12 to 20 nM, n = 52) with 
SSR97213 being less active (IC50 = 77 nM; 75 % CIs = 
14 to 205 nM), and no significant cross-sensitivity 
between FQ and other antimalarials was detected; 
consequently FQ may be a suitable replacement for 
chloroquine in the treatment of drug-resistant P. vivax 
malaria (Leimanis et al., 2010). In the Gabonese study 
(Kreidenweiss et al., 2006), IC99s were reported in 
comparison with IC50s (Kreidenweiss et al., 2006). For 
artesunate and FQ, the IC99s were 5.76 nM (95 % CIs = 
0.57 to 49.1 nM) or IC50 = 2.21 ng/mL (95 % CIs = 
0.22 to 18.9 ng/mL), and 5.75 nM (95 % CIs = 1.10 
to 56.9 nM) or IC50 = 2.50 ng/mL (95 % CIs = 0.48 to 
24.8 ng/mL). These values are close to the reported 
IC50s, indicating a strong potency and the ability to 
efficiently kill all parasites present in the field isolates.
Finally, the susceptibility of P. falciparum isolates from 
Madagascar (n = 21), Guyana (n = 65) and Cambodia 
(n = 62) to FQ was measured at the local Pasteur 
Institutes using the [3H]-hypoxanthine incorporation 
method. The mean IC50 (with minimum and maximum 
IC50 values), were 5.96 nM (0.2-43.2), 8.68 nM (3.05-
55.77) and 10.18 nM (2.53-43.43), respectively (Eric 
Legrand, personal communication).
In all studies, no cross-resistance was observed with 
CQ and other antimalarials, although weak occur-
rences could be attributed, in one study to fluctuations 
of initial inoculums used for test (Kreidenweiss et al., 
2006). This absence of cross-resistance is supported 
by molecular studies, which showed that there was 
no association between polymorphims of resistance 
of pfcrt gene, the main molecular marker for CQ, and 
FQ susceptibility in field isolates (Daher et al., 2006b). 
This last observation was then extended to other mar-
kers of quinoline resistance (Henry et al., 2008) and 
to pymdr and pycrt genes of the rodent strain P. yoelii 
(Dive & Biot, 2008).
RESISTANCE ACQUISITION UNDER FERROQUINE 
PRESSURE
An in vitro study on P. falciparum resistance acqui-
sition under ferroquine pressure was performed on 
human red blood cells infected with the W2 clone. 
After two months of FQ pressure we were unable to 
obtain a viable resistant strain. During these expe-
riments however, we observed very few parasites, 
which were unable to develop when transferred in 
drug-free medium (Daher et al., 2006b).
An attempt to obtain a rodent FQR strain starting from 
P. yoelii resulted in a phenotype that was not fixed 
genetically the resistance disappearing as soon as FQ 
pressure was removed. Moreover, the phenotype was 
emerging very slowly and was confined strictly to 
reticulocytes and easily cleared by the host (Dive & 
Biot, 2008).
These results clearly show that the fitness cost of 
FQ resistance is very high for the parasite and that it 
would be detrimental for them in competition with 
non-resistant clones. 
Country
Ferroquine Chloroquine Artesunate
Referencen
IC50 (nM)
(ng/mL)
95 %
CI n
IC50 (nM)
(ng/mL)
95 %
CI
%
resistance n
IC50 (nM)
(ng/mL)
95 %
CI
Gabon
Senegal
Gabon
Gabon
Thailand
Gabon
Cambodia
103
 55
 56
 60
 65
 40
155
10.8
 4.7
 7.9
 3.4
16
 6.9
27.9
12.1
 9.3
 4.0
 1.9
 0.8
29
12.6
8.6-13.5
3.8-5.9
6.5-9.7
2.8-4.2
14.4-17.8
 6.3-7.8
 2.3-33.2
 1.0-14.5
 8.7-10.0
3.8-4.4
0.6-6.7
0.3-3.0
26.3-31.6
11.6-13.8
102
 53
 56
 60
 62
 43
155
370
118.4
102
 32.6
141
 45.1
398
127.3
341
109.1
113
 36.1
135
 43.1
319-429
102-137
 74-140
23.7-44.8
 70-285
22.4-91.2
166-956
53.1-306
304-382
87.2-122
12.4-332
4.0-106
121-151
38.7-48.2
 95 (a)
 55 (a)
 52 (a)
 97 (a)
100 (a)
100 (b)
 32 (a)
 65
 51
 nt
 nt
 56
 43
150
2.9
1.1
1.9
0.7
nt
nt
4.0
1.5
1.0
0.4
1.1
0.4
2.3-3.7
0.9-1.4
1.5-2.3
0.6-0.9
nt
nt
3.1-6.3
1.2-2.4
0.2-6.0
0.1-2.3
1.0-1.2
0.4-0.5
Biot et al., 
1999
Biot et al., 
2006a
Daher et al., 
2006a
Daher et al., 
2006a
Daher et al., 
2006b
Delhaes et al., 
2001
EVT0231
n = number of clinical sites; nt = not tested; CI = confidence interval; IC50 = inhibitory concentration decreasing a response by 50 %; (a) = % 
of resistance using the threshold level of resistance IC50 > 100 nM; (b) = % of resistance using the threshold of IC99 > 30 nM for the HRP2 
detection assay. For values in italics, units = ng/mL, calculated for translation to a free-base or free-acid gravimetric concentration.
Table I. – Effect of FQ (SSR97193 – IC50 and 95 % confidence intervals) on P. falciparum clinical isolates from different studies.
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MODES OF ACTION: HYPOTHESES 
CQ is thought to act by interfering with the digestion of haemoglobin in the blood stages of the malaria life cycle. Even if CQ and FQ share 
some similarities in their activity, FQ clearly showed 
important and additional mechanisms of action when 
compared to CQ (Table II) (Biot et al., 2005; Dubar 
et al., 2011).
The weaker base properties of FQ compared to CQ 
combined with its higher lipophilicity at pH 7.4 and 
the peculiar conformation provided by the intra-mole-
cular hydrogen bond present in non polar conditions 
result in a better potency for FQ to cross membranes 
and a higher accumulation in the digestive vacuole. At 
the pH in that organelle, the physicochemical proper-
ties of FQ evidenced a higher fraction of neutral and 
mono-protonated forms and suggested a more efficient 
inhibitory activity on hematin biocrystallization (Dubar 
et al., 2011), which was verified in vitro in BHIA 
(β-Hematin Inhibition Assay). Moreover, preferential 
localization of FQ at the site of crystallization of hemo-
zoin close to the membrane of acidic vacuole might 
induce two independent or concomitant behaviours: 
first FQ might inhibit the self assembly of the hemo-
zoin crystal and second FQ might specifically generate 
reactive oxygen species (per se, or via destruction of 
the hemozoin crystal) and induce lipid peroxidation 
Properties CQ FQ
Intramolecular hydrogen bond
Weak base properties (pKa1 and pKa2 
values)
Neutral and protonated forms at vacuolar 
pH
Lipophilicity at pH 5.2
Lipophilicity at pH 7.4
Complex with hematin and stoichiometry
Interaction with monomeric hematin 
(log K)
Inhibition of β-hematin formation (IRS)
BHIA50
Production of hydroxyl radicals
Activity on CQR clones and isolates
Relation with specific molecular 
resistance markers
Yes
10.03
and 7.94
One time
- 1.2
0.85
Yes (1:1)
Yes (5.52)
Yes
1.9
No
No
Yes
Yes
8.19
and 6.99
Ten times
- 0.77
2.95
Yes (1:1)
Yes (5.52)
Yes
0.78
Yes
Yes
No
IRS = infrared spectroscopy. BHIA50 = 50 % inhibitory concentration 
for β-hematin inhibition in equivalents of compounds to hemin 
(Biot et al., 2005).
Table II. – Comparative properties of chloroquine (CQ) and ferro-
quine (FQ).
and alteration of digestive vacuole (Chavain et al., 
2008; Dubar et al., 2011).
All these properties might explain why FQ is more 
active than CQ in vitro even in a susceptible P. falci-
parum clone. The in vitro assays emphasized the 
specific importance of the intra-molecular hydrogen 
bond in FQ. Indeed in our studies based on methyl-
FQ (an analogue of FQ without the intra-molecular 
hydrogen bond due to the presence of a methyl group 
on the 4-amino group), we clearly showed that the 
presence of the intra-molecular hydrogen bond allows 
FQ to escape resistance mechanisms and avoid cross- 
resistance with the current antimalarials (Biot et al., 
2009; Dubar et al., 2011). 
CLINICAL TRIALS
A total of 335 subjects, or patients have been administered with FQ (SSR97193) as of June 28 2010. In seven completed Phase 1/2 studies, 
173 males subjects/patients were part of two trials 
performed in healthy Caucasian subjects, four trials 
conducted in asymptomatic African patients infected 
with P. falciparum, and one Phase IIa dose-escalation 
safety and activity (including adult African patients with 
mono-infection with P. falciparum and parasitemia 
within the 100 to 200,000/μL limits). Ongoing phase IIb 
dose-range study accounting for 440 patients conducted 
across seven African countries is currently assessing in 
four groups the safety and efficacy of an association of 
FQ-at a three dose level- with artesunate and FQ alone 
in patients with mono infection with P. falciparum. The 
first and second cohort consisting of adult/adolescent 
patients and children > 20 kg has been completed. 
Other potential combinations and indications are 
under evaluation at the time of writing this review. 
CONCLUSIONS AND PERSPECTIVES
In conclusion, FQ clinical trials will enable the definition of conditions of use of this new anti-malarial drug, which appears to be well positioned 
in the pipeline. One remaining question is the cause 
of the potent activity of the drug, mainly towards CQ 
resistant parasites, and its relation with the structure 
of the molecule. Some clues (role of the hydrogen 
bond, role of redox activity, nature of the metal pre-
sent in the metallocene moiety) are currently under 
examination to clarify the mechanisms of entry of FQ 
in the infected red blood cell, its site and mechanism 
of action and its relation with the transporters involved 
in resistance against different aminoquinolines, which 
appear ineffective to expel the molecule out of the 
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parasite. On the clinical front, it remains to determine 
how this new drug will be best combined with a par-
tner to limit the risk of resistance.
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